The Vistin Pharma ASA board proposed an extraordinary dividend of 7 Norwegian kroner per share after completing the sale of its opioids and tablet manufacturing business to TPI Enterprises Ltd.

The company expects a positive net cash effect between 140 million kroner to 150 million kroner, before any transaction costs, from the sale of the assets.

As of Oct. 6, US$1 was equivalent to 8.01 Norwegian kroner.